Bibliography
- Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies. Drug Discov Today 2007;12:472-8
- Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004;117(12A):S24-32
- GINA (Global Initiative for asthma) report 2006 – Global strategy for asthma management and prevention. Available from: www.ginasthma.org
- GOLD (Global initiative for chronic obstructive lung disease) report 2006 – Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: www.goldcopd.org
- van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-22
- van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-17
- Rossoni G, Manfedi B, Razzetti R, et al. Positive interaction of the novel β2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther 2007;20:250-7
- Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98:1214-21
- Di Marco F, Verga M, Santus P, et al. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006;100:1925-32
- Singh D, Brooks J, Hagan G, et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-8
- Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann Intern Med 2007;146:545-55
- Theravance Press release (last checked September 2008) Available from: http://ir.theravance.com/ReleaseDetail.cfm?ReleaseID=322048
- Morphy R, Rankovic Z. The Physicochemical Challenges of Designing Multiple Ligands. J Med Chem 2006;49:4961-70. and Designed Multiple Ligands. J Med Chem 2005;48:6523-43
- Yamanouchi. WO1995021820. See also Naito R, Takeuchi M, Morihira K, et al. Selective muscarinic antagonists. I. Synthesis and antimuscarinic properties of biphenylcarbamate derivatives. Chem Pharm Bull 1998;46:1274-85
- Theravance, Inc. WO04074246
- Theravance, Inc. WO05080375
- Theravance, Inc. WO06023454
- Theravance, Inc. WO07090859
- ClinTrials.Gov website (last checked September 2008). Available from: http://clinicaltrials.gov/ct2/show/NCT00550225?term=GSK961081&rank=3
- Theravance, Inc. WO04074276
- Theravance, Inc. WO04074812
- Theravance, Inc. WO05051946
- Bonnert RV, Brown RC, et al. Dual D2-Receptor and β 2-Adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-Aminoethyl)-4-hydroxybenzothiazol-2(3H )-one analogues. J Med Chem 1998;41:4915-7
- Theravance, Inc. WO06023457. See also Norman P. Dual-acting β2 agonists/muscarinic antagonists. Expert Opin Ther Patents 2006;16:1327-31
- Theravance, Inc. WO06023460
- Theravance, Inc. WO07127196
- Theravance, Inc. WO07127297
- Theravance, Inc. WO04089892
- Theravance, Inc. WO04106333
- See Argenta Discovery website, last checked 25/09/08. Available from: http://www.argentadiscovery.com/news/press_releases/archive/310107_argenta_astrazeneca.html
- Argenta Discovery. WO07017669
- Argenta Discovery. WO08017827
- Argenta Discovery/AstraZeneca. WO08023157
- Argenta Discovery/AstraZeneca. WO08096129
- Argenta Discovery. WO07017670
- Argenta Discovery/AstraZeneca. WO08096127
- Argenta Discovery. WO08017824
- Boehringer-Ingelheim Corp. US20050256114
- Novartis. AG. WO08000483
- Pfizer, Inc. WO07107828
- See for example WO05080324. Pfizer Inc. as an example of Pfizer's β2-agonist patent estate containing the arylsulfonamide motif
- Pfizer, Inc. WO08041095
- Motomura S, Reinhard-Zerkowski H, Daul A, et al. On the physiological role of beta-2 receptors in the human heart: in vitro and in vivo studies. Am Heart J 1990;119:608-19
- Tashkin DP, Celli B, Senn S, et al. A four year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1616-8
- Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting beta-agonists in COPD: a systematic review. Chest 2008;133(5):1079-87